# Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

> **NCT02774291** · EARLY_PHASE1 · TERMINATED · sponsor: **Albert Einstein College of Medicine** · enrollment: 3 (actual)

## Conditions studied

- HLA-A2 Positive Cells Present
- Metastatic Malignant Neoplasm
- Metastatic Malignant Neoplasm in the Brain

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02774291
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-20
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-08-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Due to lack of accrual the study was formally terminated on 01-JUL-2020. Primary Completion and Study Completion Dates have been revised based accordingly based on respective definitions
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02774291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02774291, "Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02774291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*